Medical device developer Jeffrey Greiner currently serves as CEO of Valencia Technologies Corporation, a medical technology company that develops and manufactures neuromodulation technologies and products. Greiner takes a keen interest in the potential of neuromodulation to treat a variety of medical conditions and is especially enthusiastic about possible advances in the field of spinal cord stimulation. Greiner formerly led Advanced Bionics as its chief executive officer.
Spinal cord stimulation, a type of neuromodulation, modifies neural activity by delivering mild electrical impulses to nerves along the spinal column via implants. First used to treat back pain in 1967, the therapy was approved by the U.S. Food and Drug Administration in 1989 as a method of relieving neural-related pain in the torso, arms, or legs. Spinal cord stimulation currently accounts for a large percentage of all medical neuromodulation treatments.
Spinal cord stimulation appears to work in two ways: first, by reducing the number of pain signals traveling through the spine, and second, by stimulating spinal nerves to release pain-relieving chemicals. The procedure also improves circulation to the affected region. Increased oxygenation is a potential factor in reducing pain caused by ischemia.
Spinal cord stimulation has proven to be effective in treating pain. In fact, more than 60 percent of candidates who receive the treatment find their pain reduced by 50 to 70 percent, resulting in significant improvement in their quality of life.
Medical device developer Jeffrey Greiner is the former CEO of Advanced Bionics, a firm which manufactures and sells cochlear implants, and is now part of Sonova, the Swiss hearing aid giant. Jeff Greiner is enthusiastic about combining the hearing aid advances of Sonova’s Phonak products along with the sophisticated signal processing of Advanced Bionics’ present technology.
Advanced Bionics’ cochlear implants now incorporate some of the most state-of-the-art technology available in the field, including the exclusive Phonak Binaural VoiceStream Technology™ and ClearVoice™, which allow implant recipients to isolate and hear speech better in noisy situations. Binaural VoiceStream Technology allows people with hearing impairments to negotiate particularly challenging situations, permitting them to hear speech on especially windy days and in noisy crowds. It enables them to focus either automatically or manually on the clearest speech source in these environments and provides more signal and thus better understanding.
The technology also gives more and better high frequency audibility and reduces feedback, reverberation and echoes. Finally, Phonak technology adaptively increases sound amplification levels in order to let new users acclimate themselves gradually to their new hearing implants until their pre-determined target is reached.
Jeffrey Greiner is the chief executive officer of Valencia Technologies Corporation in Valencia, California. A veteran of the medical technology field, Greiner previously served as chief executive officer at Advanced Bionics, one of the world’s leading developers of cochlear implants.
Cochlear implants help people who are deaf hear by converting sound waves into electrical signals. These signals are sent to the brain, which perceives them as sound. Approximately 188,000 people worldwide have cochlear implants, most of which provide good enough sound quality to enable them to understand speech in quiet environments.
The newest generation of cochlear implants promises people clearer sound, delivered through innovative technological advances. One new technology, being developed by engineers at the Georgia Institute of Technology, uses a configuration of electrodes that are three times more sensitive than traditional wire electrodes, but which do not add to the overall size and weight of the electrode configuration. The researchers hope that the new technology will reduce the incidence of muffled or dampened sound and produce better sound quality overall.